Page 18 - Lupin

Lupin looks to strengthen brand, specialty business in the US

Company's CFO said launch of Methergine oral tablets will have a positive impact on Lupin's US revenues

Lupin gains on re-introducing Methergine oral tablets in US

The company has re-introduced Methergine Oral tablets 0.2mg for the management of PPH

Lupin strengthens branded drug business in US

The drug, Methergine, is the only FDA approved oral uterotonic and Lupin has created of a specialised sales force to drive product sales

Lupin launches generic Femhrt tablets in US

The product is generic version of Warner Chilcott's Femhrt tablets in the same strengths, Lupin said

Lupin gains on launch of first product from GAVIS pipeline in the US

The US arm has launched Zolpidem Sublingual Tablets, 1.75mg & 3.5mg used for treatment of insomnia

Lupin launches generic insomnia drug in US

Reacting to the news, stock of Lupin was trading at Rs 1,465.30 on BSE, up 0.27% from the previous close

Stocks drop for second day as Lupin falls most since '08

Stocks fell for a second day in volatile trading, as drugmakers countered advances in automakers before the expiry of the monthly derivatives series on Thursday

Lupin gets three observations from USFDA for Mandideep plant

Audit was conducted at Mandideep location; observations received are minor in nature and will not lead to disruption of product supply

Nifty Pharma index hits 52-week low; Lupin at 18-month low

At 10:43 AM, the Nifty Pharma index was down 4% as compared to a marginal 0.14% decline in the Nifty 50 index

Lupin dips on USFDA observations on Goa facility

The stock dipped 7% to Rs 1,736 on the BSE in intra-day trade.

Lupin completes $880-mn Gavis purchase

US business contributes around 45% of Lupin's revenue.